Literature DB >> 11988088

Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure.

André B P van Kuilenburg1, Doreen Dobritzsch, Rutger Meinsma, Janet Haasjes, Hans R Waterham, Malgorzata J M Nowaczyk, George D Maropoulos, Guido Hein, Hermann Kalhoff, Jean M Kirk, Holger Baaske, Anne Aukett, John A Duley, Kate P Ward, Ylva Lindqvist, Albert H van Gennip.   

Abstract

Dihydropyrimidine dehydrogenase (DPD) deficiency is an autosomal recessive disease characterized by thymine-uraciluria in homozygous deficient patients. Cancer patients with a partial deficiency of DPD are at risk of developing severe life-threatening toxicities after the administration of 5-fluorouracil. Thus, identification of novel disease-causing mutations is of the utmost importance to allow screening of patients at risk. In eight patients presenting with a complete DPD deficiency, a considerable variation in the clinical presentation was noted. Whereas motor retardation was observed in all patients, no patients presented with convulsive disorders. In this group of patients, nine novel mutations were identified including one deletion of two nucleotides [1039-1042delTG] and eight missense mutations. Analysis of the crystal structure of pig DPD suggested that five out of eight amino acid exchanges present in these patients with a complete DPD deficiency, Pro86Leu, Ser201Arg, Ser492Leu, Asp949Val and His978Arg, interfered directly or indirectly with cofactor binding or electron transport. Furthermore, the mutations Ile560Ser and Tyr211Cys most likely affected the structural integrity of the DPD protein. Only the effect of the Ile370Val and a previously identified Cys29Arg mutation could not be readily explained by analysis of the three-dimensional structure of the DPD enzyme, suggesting that at least the latter might be a common polymorphism. Our data demonstrate for the first time the possible consequences of missense mutations in the DPD gene on the function and stability of the DPD enzyme.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11988088      PMCID: PMC1222557          DOI: 10.1042/bj3640157

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  25 in total

1.  Subcellular localization of dihydropyrimidine dehydrogenase.

Authors:  A B Van Kuilenburg; H Van Lenthe; R J Wanders; A H Van Gennip
Journal:  Biol Chem       Date:  1997-09       Impact factor: 3.915

2.  Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group.

Authors:  S E Antonarakis
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

3.  Cloning and initial characterization of the human DPYD gene promoter.

Authors:  E S Collie-Duguid; S J Johnston; R H Powrie; G Milano; M C Etienne; B Rochat; G C Watson; H L McLeod
Journal:  Biochem Biophys Res Commun       Date:  2000-04-29       Impact factor: 3.575

4.  Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency.

Authors:  A B Van Kuilenburg; H Van Lenthe; A Tromp; P C Veltman; A H Van Gennip
Journal:  Clin Chem       Date:  2000-01       Impact factor: 8.327

5.  Known variant DPYD alleles do not explain DPD deficiency in cancer patients.

Authors:  E S Collie-Duguid; M C Etienne; G Milano; H L McLeod
Journal:  Pharmacogenetics       Date:  2000-04

Review 6.  Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects.

Authors:  A H van Gennip; N G Abeling; P Vreken; A B van Kuilenburg
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

7.  Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W.

Authors:  P Vreken; A B Van Kuilenburg; R Meinsma; A H van Gennip
Journal:  Hum Genet       Date:  1997-12       Impact factor: 4.132

Review 8.  Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency.

Authors:  A B Van Kuilenburg; P Vreken; N G Abeling; H D Bakker; R Meinsma; H Van Lenthe; R A De Abreu; J A Smeitink; H Kayserili; M Y Apak; E Christensen; I Holopainen; K Pulkki; D Riva; G Botteon; E Holme; M Tulinius; W J Kleijer; F A Beemer; M Duran; K E Niezen-Koning; G P Smit; C Jakobs; L M Smit; A H Van Gennip
Journal:  Hum Genet       Date:  1999-01       Impact factor: 4.132

9.  Characterization of the human dihydropyrimidine dehydrogenase gene.

Authors:  X Wei; G Elizondo; A Sapone; H L McLeod; H Raunio; P Fernandez-Salguero; F J Gonzalez
Journal:  Genomics       Date:  1998-08-01       Impact factor: 5.736

10.  Inactivation of dihydropyrimidine dehydrogenase by 5-iodouracil.

Authors:  D J Porter; W G Chestnut; L C Taylor; B M Merrill; T Spector
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

View more
  27 in total

1.  Analysis of pyrimidine catabolism in Drosophila melanogaster using epistatic interactions with mutations of pyrimidine biosynthesis and beta-alanine metabolism.

Authors:  John M Rawls
Journal:  Genetics       Date:  2005-12-15       Impact factor: 4.562

Review 2.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.

Authors:  M Wasif Saif; Adam M Lee; Steven M Offer; Kathleen McConnell; Valerie Relias; Robert B Diasio
Journal:  Mayo Clin Proc       Date:  2014-01       Impact factor: 7.616

4.  DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

Authors:  Adam M Lee; Qian Shi; Emily Pavey; Steven R Alberts; Daniel J Sargent; Frank A Sinicrope; Jeffrey L Berenberg; Richard M Goldberg; Robert B Diasio
Journal:  J Natl Cancer Inst       Date:  2014-11-07       Impact factor: 13.506

5.  Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.

Authors:  Steven M Offer; Natalie J Wegner; Croix Fossum; Kangsheng Wang; Robert B Diasio
Journal:  Cancer Res       Date:  2013-01-17       Impact factor: 12.701

6.  Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3).

Authors:  André B P van Kuilenburg; Judith Meijer; Adri N P M Mul; Raoul C M Hennekam; Jan M N Hoovers; Christine E M de Die-Smulders; Peter Weber; Andrea Capone Mori; Jörgen Bierau; Brian Fowler; Klaus Macke; Jörn Oliver Sass; Rutger Meinsma; Julia B Hennermann; Peter Miny; Lida Zoetekouw; Raymon Vijzelaar; Joost Nicolai; Bauke Ylstra; M Estela Rubio-Gozalbo
Journal:  Hum Genet       Date:  2009-03-19       Impact factor: 4.132

7.  Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.

Authors:  Keiko Maekawa; Mayumi Saeki; Yoshiro Saito; Shogo Ozawa; Kouichi Kurose; Nahoko Kaniwa; Manabu Kawamoto; Naoyuki Kamatani; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Kuniaki Shirao; Yasuhiro Shimada; Manabu Muto; Toshihiko Doi; Atsushi Ohtsu; Teruhiko Yoshida; Yasuhiro Matsumura; Nagahiro Saijo; Jun-Ichi Sawada
Journal:  J Hum Genet       Date:  2007-09-09       Impact factor: 3.172

8.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.

Authors:  Ursula Amstutz; Linda M Henricks; Steven M Offer; Julia Barbarino; Jan H M Schellens; Jesse J Swen; Teri E Klein; Howard L McLeod; Kelly E Caudle; Robert B Diasio; Matthias Schwab
Journal:  Clin Pharmacol Ther       Date:  2017-11-20       Impact factor: 6.875

9.  Head imaging abnormalities in dihydropyrimidine dehydrogenase deficiency.

Authors:  G M Enns; A J Barkovich; A B P van Kuilenburg; M Manning; T Sanger; D R Witt; A H van Gennip
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

10.  Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.

Authors:  Eva Gross; Birgit Busse; Matthias Riemenschneider; Steffi Neubauer; Katharina Seck; Hanns-Georg Klein; Marion Kiechle; Florian Lordick; Alfons Meindl
Journal:  PLoS One       Date:  2008-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.